Skip to nav Skip to content

Clinical Trial Search

305 Clinical Trials Found

Clinical Trial 21459

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Disease Site: Colon
PI: Imanirad, Iman

Clinical Trial 23101

Disease Site: Other Hematopoietic
PI: Fernandez, Hugo

Clinical Trial 22464

Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: A Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)
Disease Site: Thyroid
PI: Agosto Salgado, Sarimar

Clinical Trial 19722

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment
Disease Site: Multiple Myeloma
PI: Alsina, Melissa

Clinical Trial 21894

Phase 1 Clinical Trial of lntravesical Adoptive Cell Therapy {ACT) with Tumor Infiltrating Lymphocytes (TIL) for Patients with BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer {NMIBC)
Disease Site: Urinary Bladder
PI: Poch, Michael

Clinical Trial 21193

Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 20274

A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Disease Site: Lip, Oral Cavity and Pharynx
PI: Kirtane, Kedar

Clinical Trial 21559

Disease Site: Prostate
PI: Zhang, Jingsong

Clinical Trial 20870

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Disease Site: Other Female Genital, Ovary
PI: Chern, Jing-Yi

Clinical Trial 21416

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Disease Site: Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 22199-C

TACTIVE-U: An Interventional Safety and Efficacy Phase 1b/2, Open-Label Umbrella Study to Investigate Tolerability, PK, and Antitumor Activity of Vepdegestrant (ARV-471/PF-07850327), an Oral Proteolysis Targeting Chimera, in Combination with Other Anticancer Treatments in Participants Aged 18 and Older with ER+ Advanced or Metastatic Breast Cancer, Sub-Study C (ARV-471 in Combination with Samuraciclib)
Disease Site: Breast
PI: Han, Heather

Clinical Trial 21996

Disease Site: Other Skin
PI: Khushalani, Nikhil